Sumitomo Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SUMITOMO PHARMA, and when can generic versions of SUMITOMO PHARMA drugs launch?
SUMITOMO PHARMA has five approved drugs.
There are forty-nine US patents protecting SUMITOMO PHARMA drugs.
There are five hundred and thirty-nine patent family members on SUMITOMO PHARMA drugs in forty-one countries and forty supplementary protection certificates in fifteen countries.
Summary for Sumitomo Pharma
| International Patents: | 539 |
| US Patents: | 49 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Sumitomo Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-002 | Nov 8, 2013 | AB | RX | Yes | No | 10,912,781 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-004 | Nov 8, 2013 | AB | RX | Yes | Yes | 10,675,287 | ⤷ Sign Up | ⤷ Sign Up | |||
| Sumitomo Pharma | MYFEMBREE | estradiol; norethindrone acetate; relugolix | TABLET;ORAL | 214846-001 | May 26, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sumitomo Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | 9,931,305 | ⤷ Sign Up |
| Sumitomo Pharma Am | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | 8,511,581 | ⤷ Sign Up |
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-004 | May 21, 2020 | 11,077,068 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Sumitomo Pharma Drugs
Supplementary Protection Certificates for Sumitomo Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1453521 | 93156 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211 |
| 1453521 | CA 2016 00016 | Denmark | ⤷ Sign Up | PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211 |
| 0751129 | 09C0040 | France | ⤷ Sign Up | PRODUCT NAME: ESLICARBAZEPINE ACETATE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/514/001 DU 20090421; REGISTRATION NO/DATE AT EEC: EU/1/09/514/001 DU 20090421 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
